{"id":"double-blind-pr-oros-methylphenidate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By increasing the levels of these neurotransmitters, methylphenidate helps to improve attention and reduce impulsivity in individuals with attention deficit hyperactivity disorder (ADHD).","oneSentence":"Methylphenidate is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:49.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention deficit hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT00714688","phase":"PHASE3","title":"A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2008-02","conditions":"Attention Deficit/ Hyperactivity Disorder","enrollment":279},{"nctId":"NCT00307684","phase":"PHASE3","title":"Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2006-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":155},{"nctId":"NCT00482313","phase":"PHASE3","title":"Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Psychiatry Karolinska","startDate":"2007-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"double blind PR OROS methylphenidate","genericName":"double blind PR OROS methylphenidate","companyName":"Janssen-Cilag International NV","companyId":"janssen-cilag-international-nv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Double-blind studies have evaluated the effectiveness and safety of prolonged release (PR) OROS methylphenidate in adults with Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Disorder With Hyperactivity, and Attention Deficit Hyperactivity Disorder. Prolonged release (PR) OROS methylphenidate is a small molecule that acts as a dopamine transporter inhibitor, specifically targeting the sodium-dependent dopamine transporter.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}